A review of studies on the efficacy of single-dose human papillomavirus (HPV) vaccination over the past few years at the WHO Strategic Advisory Group of Experts on Immunization from April 4 to April 7 concluded that single-dose human papillomavirus (HPV) vaccination The sub-HPV vaccination regimen was effective in preventing cervical cancer caused by persistent HPV infection, as effective as a two- or three-dose regimen.
A single shot of the three-shot HPV vaccine is enough? On April 16, a media spokesperson at Merck’s headquarters responded that there is still a huge data gap for the single-dose regimen or other programs that are not currently licensed by regulatory authorities. “The draft high-level recommendations of the WHO Strategic Advisory Group of Experts on Immunization are not final and are subject to review by the WHO Director-General. These reports are only considered final when they are published in the Weekly Epidemiological Record.”
MSD, as an HPV vaccine production and research company, according to the financial report data of Merck in recent years, Gardasil/Gardasil9 (Gardasil®) (4/9 price human papillomavirus vaccine) sales performance in 2018 was 31.51% The sales performance in 2019 is US$3.737 billion; the sales performance in 2020 is US$3.938 billion; the sales performance in 2021 is as high as US$5.7 billion.
On April 16, Professor Wei Lihui, chairman of the Colposcopy and Cervical Cancer Pathology Branch of the Chinese Eugenics Association and honorary director of the Department of Obstetrics and Gynecology of Peking University, said in an interview with the Securities Times that due to limited evidence, ( Only one dose of HPV vaccine) cannot be considered as the best practice for HPV vaccination, and more and more comprehensive research data need to be accumulated to support it. In view of the large population in my country and the large demand for HPV vaccine, the current vaccine cannot meet the vaccination needs of Chinese women. In addition, the vaccination rate of 9-14-year-old girls who benefit the most from HPV vaccine is less than 2%. Therefore, we still advocate three-dose full-course vaccination; we advocate early vaccination for adolescent girls; it is better to advocate vaccination than no vaccination.
Professor Wei Lihui
For HPV vaccine “one needle over three needles”, Professor Wei Lihui explained, WHO Immunization Strategy Expert Group It is proposed that only one dose of HPV vaccine can produce the same immune effect as 2 to 3 doses. This new recommendation is based on concerns about the slow introduction of HPV vaccine into immunization programs and low overall population coverage. Based on the current situation of increasing cervical cancer incidence and mortality, this vaccination program is recommended to accelerate the goal of eliminating cervical cancer. This is the World Health Organization’s recommendation from the perspective of global accessibility, which is more economical and practical, especially for women in the third world to obtain vaccination services. (Lu Yang)